These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22555080)

  • 21. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Potential role of rilpivirine in simplification regimens].
    Casado JL; Moreno S
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():30-5. PubMed ID: 24252531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rilpivirine.
    Sanford M
    Drugs; 2012 Mar; 72(4):525-41. PubMed ID: 22356290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
    Fernández-Montero JV; Vispo E; Anta L; de Mendoza C; Soriano V
    Expert Opin Pharmacother; 2012 May; 13(7):1007-14. PubMed ID: 22519768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetic interactions].
    Arazo Garcés P; de los Santos Gil I
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():12-9. PubMed ID: 24252529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Ripamonti D; Maggiolo F
    Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
    Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
    Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
    Cohen CJ; Molina JM; Cassetti I; Chetchotisakd P; Lazzarin A; Orkin C; Rhame F; Stellbrink HJ; Li T; Crauwels H; Rimsky L; Vanveggel S; Williams P; Boven K;
    AIDS; 2013 Mar; 27(6):939-950. PubMed ID: 23211772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
    Ripamonti D; Bombana E; Rizzi M
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
    Rimsky L; Vingerhoets J; Van Eygen V; Eron J; Clotet B; Hoogstoel A; Boven K; Picchio G
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):39-46. PubMed ID: 22067667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
    Jayaweera D; Dilanchian P
    Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
    Snopková S; Havlíčková K; Polák P; Šlesinger P; Husa P
    Klin Mikrobiol Infekc Lek; 2013 Mar; 19(1):19-22. PubMed ID: 23945833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine.
    Casado JL
    AIDS Rev; 2013; 15(3):139-45. PubMed ID: 24002197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
    Crauwels H; Vingerhoets J; Ryan R; Witek J; Anderson D
    Antivir Ther; 2012; 17(3):439-46. PubMed ID: 22293086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.